Table 2. Genotype frequencies of the TNF promoter, TNF receptor II and TNF receptor I promoter polymorphisms in transplant patients with and without PTLD.

Polymorphism	Genotype	Transplant subjects without PTLD (n=65) freq (%)	Transplant subjects with PTLD (n=45) freq (%)	P-valuea	Healthy control subjects (n=183) freq (%)	P-valuea,b
TNF-α promoter
−1031	TT	65	44	0.01*	57	0.001*
	TC	32	38		40
	CC	3	9		3
−863	CC	82	44	0.0003*	73	0.0007*
	CA	15	47		25
	AA	3	9		2
−857	CC	89	78	0.18	84	0.63
	CT	11	20		12
	TT	0	20		2
−307	GG	63	66	0.78	64	0.71
	GA	32	27		32
	AA	5	7		4
−237	GG	88	98	0.08	40	0.10
	GA	12	2		10
	AA	0	0		0
TNF receptor II
−1663	AA	18	20	0.39	26	0.53
	AG	35	55		45
	GG	31	25		29
−1668	TT	91	90	0.89	80	0.14
	TG	9	10		20
	GG	0	0		0
−1690	CC	11	16	0.25	18	0.75
	CT	52	48		41
	TT	37	36		41
−676	TT	65	64	0.97	52	0.32
	TG	28	29		38
	GG	8	7		10
TNF receptor I promoter
−201	GG	31	47	0.03*	26	0.006*
	GT	48	49		54
	TT	20	4		20
−230	AA	100	96	0.08	98	0.25
	AG	0	4		2
	GG	0	0		0
−845	AA	38	20	0.12	37	0.02*
	AG	48	58		53
	GG	14	22		9
−839	GG	95	96	0.96	97	0.73
	GA	5	4		3
	AA	0	0		0
−1135	TT	17	4	0.06	20	0.005*
	TC	52	49		54
	CC	31	47		25

Abbreviations: freq=frequency; TNF=tumour necrosis factor.

^aChi-square 3 × 2 contingency table (not adjusted for multiple testing).

^bComparison between post-transplant lymphoproliferative disease (PTLD) and healthy control groups; ^*significant P-value, P<0.05.